Raymond W. Cohen left the role of Director at InspireMD, Inc., effective July 1, 2026. As of November 6, 2026, InspireMD, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from May 22, 2026 to July 2, 2026, naming 2 departures (Form 8-K, July 2, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like InspireMD, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
InspireMD, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-05-22 to 2026-07-02. They name 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as InspireMD, Inc. files it.
Also on the record for InspireMD, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 15, 2026 | Stake report, Schedule 13G/A, by Nantahala Capital Management, LLC | 9.99% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Velan Capital Master Fund LP | 4.99% of the class | 5%+ stakes | Source |
| April 24, 2026 | Stake report, Schedule 13D, by Marvin Slosman | 5.18% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by ORBIMED ADVISORS LLC | 7.4% of the class | 5%+ stakes | Source |
| February 11, 2026 | Stake report, Schedule 13G/A, by Rosalind Advisors, Inc. | 9.2% of the class | 5%+ stakes | Source |
| February 2, 2026 | Stake report, Schedule 13G/A, by Aberdeen Group plc | 7.49% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G, by Parkman Healthcare Partners LLC | 5.8% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by MARSHALL WACE, LLP | 9.99% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Nantahala Capital Management, LLC | 9.99% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP | 5.6761% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by OrbiMed Advisors LLC | 4.1% of the class | 5%+ stakes | Source |
| November 7, 2025 | Stake report, Schedule 13G, by Aberdeen Group plc | 5.95% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs InspireMD, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on InspireMD, Inc. and the records around it.
InspireMD, Inc. elsewhere on the record
- 5%+ stake filings May 2026
- Form D filing Aug 2025
- Who owns it
Companies that share a holder
- Velan Capital Master Fund LP also filed stake reports on 2 other companies: Edesa Biotech, Inc. (Aug 2026), Jasper Therapeutics, Inc. (Aug 2026)
- NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP also filed stake reports on 6 other companies: FEMASYS INC. (Aug 2026), AZITRA, INC. (Aug 2026), ABEONA THERAPEUTICS INC. (May 2026)
- Rosalind Advisors, Inc. also filed stake reports on 11 other companies: DELCATH SYSTEMS, INC. (Oct 2026), FEMASYS INC (Aug 2026), FENNEC PHARMACEUTICALS INC. (Aug 2026)
Watch InspireMD, Inc.
Get an email when InspireMD, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on InspireMD, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on InspireMD, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on InspireMD, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 19 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-02 | Out | Director | 2026-07-01 | 8-K, 2026-07-02 | |
| 2026-05-22 | Out | Director | 8-K, 2026-05-22 |
Who leads InspireMD, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Raymond W. Cohen, departure reported, effective 2026-07-01 (filed 2026-07-02). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on InspireMD, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at InspireMD, Inc., with the record behind each one.
Find candidates like Director at InspireMD, Inc.Every change, in the filing's words
Departing: Raymond W. Cohen, Director, effective 2026-07-01
On June 26, 2026, Mr. Raymond W. Cohen, a Class III member of the board of directors (the "Board") of InspireMD, Inc. (the "Company"), a member of the Audit Committee of the Board and a member of the Compensation Committee of the Board, tendered his resignation from the Board, effective July 1, 2026.
- Mr. Cohen's resignation from the Board was for personal considerations and not due to any disagreement with the Company, the Board or the management of the Company on any matter relating to the Company's operations, policies, practices or otherwise.
- The Nominating and Corporate Governance Committee of the Board intends to identify and evaluate suitable candidates to fill the vacancy created by Mr. Cohen's resignation.
Departing: Paul Stuka, Director
On May 20, 2026, Mr. Paul Stuka notified InspireMD, Inc. (the "Company") of his decision to not seek reelection as a Class I director of the Board of Directors of the Company (the "Board") at the Company's 2027 Annual Meeting of Stockholders (the "2027 Annual Meeting") and to retire from the Board.
- Mr. Stuka's decision did not result from any disagreement with the Company on any matter relating to the Company's operations, policies, practices or otherwise.
- Mr. Stuka is currently the Chair of the Board, the Chair of the Compensation Committee of the Board, and a member of the Audit Committee and the Nominating and Corporate Governance Committee of the Board.
- Mr. Stuka currently expects to continue to serve in such capacities until his term as a Class I director expires at the 2027 Annual Meeting.
- As part of succession planning, the Nominating and Corporate Governance Committee of the Board plans to identify and evaluate suitable candidates for the Board.
Tools for this story
Each opens in a new tab, filled in for InspireMD, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.